Добірка наукової літератури з теми "Melanoma Screening Trial (MST)"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Зміст
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Melanoma Screening Trial (MST)".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Melanoma Screening Trial (MST)"
Elwood, J. M. "Screening for Melanoma and Options For-Its Evaluation." Journal of Medical Screening 1, no. 1 (January 1994): 22–38. http://dx.doi.org/10.1177/096914139400100107.
Повний текст джерелаDjavid, Amir Reza, Connor Stonesifer, Benjamin T. Fullerton, Samuel W. Wang, Marlene A. Tartaro, Bradley D. Kwinta, Joseph M. Grimes, Larisa J. Geskin, and Yvonne M. Saenger. "Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence." Cancers 13, no. 19 (September 30, 2021): 4914. http://dx.doi.org/10.3390/cancers13194914.
Повний текст джерелаPrimiero, Clare Amy, Aideen M. McInerney-Leo, Brigid Betz-Stablein, David C. Whiteman, Louisa Gordon, Liam Caffery, Joanne F. Aitken, et al. "Evaluation of the efficacy of 3D total-body photography with sequential digital dermoscopy in a high-risk melanoma cohort: protocol for a randomised controlled trial." BMJ Open 9, no. 11 (November 2019): e032969. http://dx.doi.org/10.1136/bmjopen-2019-032969.
Повний текст джерелаMatias, Mariana, Jacinta O. Pinho, Maria João Penetra, Gonçalo Campos, Catarina Pinto Reis, and Maria Manuela Gaspar. "The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval." Cells 10, no. 11 (November 9, 2021): 3088. http://dx.doi.org/10.3390/cells10113088.
Повний текст джерелаColman, Howard, Ken Boucher, Chris Stehn, David Kircher, and Sheri Holmen. "THER-07. DEVELOPMENT OF A NEW MOLECULAR PREDICTOR FOR RISK OF BRAIN METASTASES AND EFFICACY OF TARGETED THERAPY IN MELANOMA." Neuro-Oncology Advances 1, Supplement_1 (August 2019): i12. http://dx.doi.org/10.1093/noajnl/vdz014.050.
Повний текст джерелаSarasamma, Sreeja, Yu-Heng Lai, Sung-Tzu Liang, Kechun Liu, and Chung-Der Hsiao. "The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities." International Journal of Molecular Sciences 19, no. 12 (December 7, 2018): 3929. http://dx.doi.org/10.3390/ijms19123929.
Повний текст джерелаKok, Peey-Sei, Won-Hee Yoon, Sally Lord, Ian Marschner, Michael Friedlander, and Chee Khoon Lee. "Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis." JCO Precision Oncology, no. 5 (July 2021): 1151–59. http://dx.doi.org/10.1200/po.21.00108.
Повний текст джерелаBrastianos, Priscilla Kaliopi, Erin Twohy, Carey K. Anders, A. John Iafrate, Peter A. Kaufman, Justine Vanessa Cohen, Rebecca Suk Heist, et al. "Alliance A071701: Genomically guided treatment trial in brain metastases." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): TPS2573. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps2573.
Повний текст джерелаShah, Payal D., Alexander Chan Chi Huang, Xiaowei Xu, Paul J. Zhang, Robert Orlowski, Tina Matlawski, Joanne Shea, et al. "Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 10035. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10035.
Повний текст джерелаSimonelli, Matteo, Emiliano Calvo, Diwakar Davar, Jason Melear, Donald Richards, Matthew Dallos, Martin Gutierrez, et al. "Abstract CT119: A randomized, double-blind phase 2 evaluation of the anti-IL-8 monoclonal antibody BMS-986253 + nivolumab + ipilimumab vs nivolumab + ipilimumab in patients with advanced melanoma that progressed on/after anti-PD-(L)1 therapy." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT119. http://dx.doi.org/10.1158/1538-7445.am2022-ct119.
Повний текст джерелаДисертації з теми "Melanoma Screening Trial (MST)"
(3436478), Brigid Lynch. "Implementing skin cancer screening clinics in a rural community: A case study of diffusion theory." Thesis, 2001. https://figshare.com/articles/thesis/Implementing_skin_cancer_screening_clinics_in_a_rural_community_A_case_study_of_diffusion_theory/20022704.
Повний текст джерелаSkin cancer screening clinics were introduced into a number of towns throughout Queensland as part of the Melanoma Screening Trial (MST), a study investigating the efficacy of screening for melanoma. The MST requires 60% of these towns' populations aged over 30 years to be screened for
melanoma within a three year intervention phase. The aim of this case study is to assess the relationship between Rogers' (1995) diffusion of innovations and the health promotion strategies implemented to encourage attendance at skin cancer screening clinics.
Data were obtained from a number of sources, including administrative files, progress reports, interviews and focus groups and were positioned within a comparative theory/practice matrix. Pattern matching logic was used to
assess the relationship between the health promotion strategies and the theoretical construct of diffusion of innovations.
All components of diffusion of innovations (Rogers, 1995) were addressed by the health promotion strategies encouraging attendance at the skin cancer screening clinics. The delivery of the skin cancer screening clinics was in accordance with principles identified by past diffusion research. The skin cancer screening clinics conformed to most predictors of diffusion success and were delivered within a "real" environment, as suggested by past community -based interventions. A number of changes to existing health promotion strategies and the addition of some new strategies have been suggested to improve the rate of diffusion of skin cancer screening clinics in
the future.